|
1
|
Morales E, Galindo M, Trujillo H and Praga
M: Update on lupus nephritis: Looking for a new vision. Nephron.
145:1–13. 2021. View Article : Google Scholar
|
|
2
|
Mohan C, Zhang T and Putterman C:
Pathogenic cellular and molecular mediators in lupus nephritis. Nat
Rev Nephrol. 19:491–508. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Appel GB, Contreras G, Dooley MA, Ginzler
EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J,
Solomons N, et al: Mycophenolate mofetil versus cyclophosphamide
for induction treatment of lupus nephritis. J Am Soc Nephrol.
20:1103–1112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ponticelli C and Podestà MA: Calcineurin
inhibitors in lupus nephritis. J Nephrol. 34:399–402. 2021.
View Article : Google Scholar
|
|
5
|
Yu C, Li P, Dang X, Zhang X, Mao Y and
Chen X: Lupus nephritis: New progress in diagnosis and treatment. J
Autoimmun. 132:1028712022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anders HJ, Saxena R, Zhao MH, Parodis I,
Salmon JE and Mohan C: Lupus nephritis. Nat Rev Dis Primers.
6:72020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flores-Borja F, Kabouridis PS, Jury EC,
Isenberg DA and Mageed RA: Decreased Lyn expression and
translocation to lipid raft signaling domains in B lymphocytes from
patients with systemic lupus erythematosus. Arthritis Rheum.
52:3955–3965. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liossis SN, Solomou EE, Dimopoulos MA,
Panayiotidis P, Mavrikakis MM and Sfikakis P: B-cell kinase lyn
deficiency in patients with systemic lupus erythematosus. J
Investig Med. 49:157–165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zouali M and Sarmay G: B lymphocyte
signaling pathways in systemic autoimmunity: Implications for
pathogenesis and treatment. Arthritis Rheum. 50:2730–2741. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geh D and Gordon C: Epratuzumab for the
treatment of systemic lupus erythematosus. Expert Rev Clin Immunol.
14:245–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wallace DJ and Goldenberg DM: Epratuzumab
for systemic lupus erythematosus. Lupus. 22:400–405. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arazi A, Rao DA, Berthier CC, Davidson A,
Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, et
al: The immune cell landscape in kidneys of patients with lupus
nephritis. Nat Immunol. 20:902–914. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin K, Li L, Dai Y, Wang H, Teng S, Bao X,
Lu ZJ and Wang D: A comprehensive evaluation of connectivity
methods for L1000 data. Brief Bioinform. 21:2194–2205. 2020.
View Article : Google Scholar
|
|
14
|
Subramanian A, Narayan R, Corsello SM,
Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK,
et al: A next generation connectivity map: L1000 platform and the
first 1,000,000 profiles. Cell. 171:1437–1452.e17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang Y, Jiang Q, Zou H, Zhao J, Zhang J
and Ren L: Withaferin A: A potential selective glucocorticoid
receptor modulator with anti-inflammatory effect. Food Chem
Toxicol. 179:1139492023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar S, Mathew SO, Aharwal RP, Tulli HS,
Mohan CD, Sethi G, Ahn KS, Webber K, Sandhu SS and Bishayee A:
Withaferin A: A pleiotropic anticancer agent from the indian
medicinal plant Withania somnifera (L.) Dunal. Pharmaceuticals
(Basel). 16:1602023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nisar MF, Wan C, Büsselberg D, Calina D
and Sharifi-Rad J: Current mechanistic insights into Withaferin A:
A promising potential adjuvant anticancer agent from Withania
somnifera. Naunyn Schmiedebergs Arch Pharmacol. 398:3573–3593.
2025. View Article : Google Scholar
|
|
18
|
Underwood W and Anthony R: AVMA Guidelines
for the Euthanasia of Animals: 2020 Edition. American Veterinary
Medical Association; 2020
|
|
19
|
Yang C, Xue J, An N, Huang XJ, Wu ZH, Ye
L, Li ZH, Wang SJ, Pan QJ, Liang D and Liu HF: Accelerated
glomerular cell senescence in experimental lupus nephritis. Med Sci
Monit. 24:6882–6891. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen XC, Wu D, Wu HL, Li HY, Yang C, Su
HY, Liu ZJ, Huang XR, Lu X, Huang LF, et al: Metformin improves
renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3
pathway. Lupus Sci Med. 9:e0006112022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao C, Jin W, Dou L, Guo T, Huang J, Wang
Y, Liu X, Wu S, Qiao W, Xiang Y, et al: Bioengineered ROS-tolerant
probiotic reshapes gut microbiota-host axis to ameliorate type 2
diabetes in male mice. Nat Commun. 17:33392026. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ackermann M and Strimmer K: A general
modular framework for gene set enrichment analysis. BMC
Bioinformatics. 10:472009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Parodis I, Gatto M and Sjöwall C: B cells
in systemic lupus erythematosus: Targets of new therapies and
surveillance tools. Front Med (Lausanne). 9:9523042022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmed A, Li S, Yu JJ and Shao WH:
Immunopathogenesis of systemic lupus erythematosus: Interplay of
innate and adaptive immunity, microbiome dysbiosis, and emerging
therapeutic targets. Pathophysiology. 32:612025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong C, Wu M, Liu H, Yang K, Ma S, Guo Y,
Lan Y and Lu X: Breaking the cycle: Immune complexes, complement
activation, and novel immunotherapies in lupus nephritis. Front
Immunol. 16:16248502025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dornas W and Silva M: Modulation of the
antioxidant enzyme paraoxonase-1 for protection against
cardiovascular diseases. Nutr Metab Cardiovasc Dis. 34:2611–2622.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jakubowski H: The molecular bases of
Anti-oxidative and Anti-inflammatory properties of paraoxonase 1.
Antioxidants (Basel). 13:12922024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rozenberg O, Shih DM and Aviram M:
Paraoxonase 1 (PON1) attenuates macrophage oxidative status:
Studies in PON1 transfected cells and in PON1 transgenic mice.
Atherosclerosis. 181:9–18. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sikora M and Jakubowski H: Changes in
redox plasma proteome of Pon1-/-mice are exacerbated by a
hyperhomocysteinemic diet. Free Radic Biol Med. 169:169–180. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang M, Yu X, Liu C and Liu Y:
Overexpression of PON1 reduces high glucose induced renal tubular
epithelial cell injury by activating PPARgamma signaling pathway to
alleviate diabetes nephropathy. Arch Endocrinol Metab.
69:e2403772025. View Article : Google Scholar
|
|
33
|
Zhao M, Wang B, Zhang C, Su Z, Guo B, Zhao
Y and Zheng R: The DJ1-Nrf2-STING axis mediates the neuroprotective
effects of Withaferin A in Parkinson's disease. Cell Death Differ.
28:2517–2535. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo B, Liu J, Wang B, Zhang C, Su Z, Zhao
M, Qin L, Zhang W and Zheng R: Withaferin A promotes white adipose
browning and prevents obesity through sympathetic Nerve-activated
Prdm16-FATP1 axis. Diabetes. 71:249–263. 2022. View Article : Google Scholar
|
|
35
|
Oh JH, Lee TJ, Park JW and Kwon TK:
Withaferin A inhibits iNOS expression and nitric oxide production
by Akt inactivation and down-regulating LPS-induced activity of
NF-kappaB in RAW 264.7 cells. Eur J Pharmacol. 599:11–17. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Martorana F, Guidotti G, Brambilla L and
Rossi D: Withaferin A inhibits nuclear Factor-κB-Dependent
Pro-Inflammatory and stress response pathways in the astrocytes.
Neural Plast. 2015:3819642015. View Article : Google Scholar
|
|
37
|
Mohan R, Hammers HJ, Bargagna-Mohan P,
Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP,
Rougas J and Pribluda VS: Withaferin A is a potent inhibitor of
angiogenesis. Angiogenesis. 7:115–122. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee J, Hahm ER, Marcus AI and Singh SV:
Withaferin A inhibits experimental epithelial-mesenchymal
transition in MCF-10A cells and suppresses vimentin protein level
in vivo in breast tumors. Mol Carcinog. 54:417–429. 2015.
View Article : Google Scholar
|
|
39
|
Rasool M and Varalakshmi P:
Immunomodulatory role of Withania somnifera root powder on
experimental induced inflammation: An in vivo and in vitro study.
Vascul Pharmacol. 44:406–410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yan Z, Guo R, Gan L, Lau WB, Cao X, Zhao
J, Ma X, Christopher TA, Lopez BL and Wang Y: Withaferin A inhibits
apoptosis via activated Akt-mediated inhibition of oxidative
stress. Life Sci. 211:91–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Batumalaie K, Amin MA, Murugan DD, Sattar
MZ and Abdullah NA: Withaferin A protects against palmitic
acid-induced endothelial insulin resistance and dysfunction through
suppression of oxidative stress and inflammation. Sci Rep.
6:272362016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kanak MA, Shahbazov R, Yoshimatsu G, Levy
MF, Lawrence MC and Naziruddin B: A small molecule inhibitor of
NFκB blocks ER stress and the NLRP3 inflammasome and prevents
progression of pancreatitis. J Gastroenterol. 52:352–365. 2017.
View Article : Google Scholar
|
|
43
|
Pires N, Gota V, Gulia A, Hingorani L,
Agarwal M and Puri A: Safety and pharmacokinetics of Withaferin-A
in advanced stage high grade osteosarcoma: A phase I trial. J
Ayurveda Integr Med. 11:68–72. 2020. View Article : Google Scholar :
|
|
44
|
Furlong CE, Marsillach J, Jarvik GP and
Costa LG: Paraoxonases-1, -2 and -3: What are their functions? Chem
Biol Interact. 259:51–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gugliucci A and Menini T: Paraoxonase 1
and HDL maturation. Clin Chim Acta. 439:5–13. 2015. View Article : Google Scholar
|
|
46
|
Précourt LP, Amre D, Denis MC, Lavoie JC,
Delvin E, Seidman E and Levy E: The three-gene paraoxonase family:
Physiologic roles, actions and regulation. Atherosclerosis.
214:20–36. 2011. View Article : Google Scholar
|
|
47
|
Diaz L and Bielczyk-Maczynska E:
High-density lipoprotein cholesterol: How studying the 'good
cholesterol' could improve cardiovascular health. Open Biol.
15:2403722025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yazdanyar A, Yeang C and Jiang XC: Role of
phospholipid transfer protein in high-density lipoprotein-mediated
reverse cholesterol transport. Curr Atheroscler Rep. 13:242–248.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Besler C, Lüscher TF and Landmesser U:
Molecular mechanisms of vascular effects of High-density
lipoprotein: Alterations in cardiovascular disease. EMBO Mol Med.
4:251–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gaál K, Tarr T, Lőrincz H, Borbás V, Seres
I, Harangi M, Fülöp P and Paragh G: High-density lipopoprotein
antioxidant capacity, subpopulation distribution and paraoxonase-1
activity in patients with systemic lupus erythematosus. Lipids
Health Dis. 15:602016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lilleby V, Haugen M, Mørkrid L, Frey
Frøslie K, Holven KB and Førre O: Body composition, lipid and
lipoprotein levels in childhood-onset systemic lupus erythematosus.
Scand J Rheumatol. 36:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yuan J, Li LI, Wang Z, Song W and Zhang Z:
Dyslipidemia in patients with systemic lupus erythematosus:
Association with disease activity and B-type natriuretic peptide
levels. Biomed Rep. 4:68–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi
G and Paragh G: Reduced paraoxonase1 activity is a risk for
atherosclerosis in patients with systemic lupus erythematosus. Ann
N Y Acad Sci. 1108:83–91. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guleria A, Phatak S, Dubey D, Kumar S,
Zanwar A, Chaurasia S, Kumar U, Gupta R, Aggarwal A, Kumar D and
Misra R: NMR-Based serum metabolomics reveals reprogramming of
lipid dysregulation following Cyclophosphamide-Based induction
therapy in lupus nephritis. J Proteome Res. 17:2440–2448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu H, Wu L, Luo L, Wu YT, Zhang QX, Li HY
and Zhang BF: Corrigendum to 'Quercetin inhibits mitophagy-mediated
apoptosis and inflammatory response by targeting the
PPARγ/PGC-1α/NF-κB axis to improve acute liver failure' [Int
Immunopharmacol 143P2 (2024) 113444]. Int Immunopharmacol.
143:1136792024. View Article : Google Scholar
|
|
56
|
Santana-Sánchez P, Vaquero-García R,
Legorreta-Haquet MV, Chávez-Sánchez L and Chávez-Rueda AK: Hormones
and B-cell development in health and autoimmunity. Front Immunol.
15:13855012024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang H, Wang L and Chu Y: Reactive oxygen
species: The signal regulator of B cell. Free Radic Biol Med.
142:16–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Merluzzi S, Moretti M, Altamura S, Zwollo
P, Sigvardsson M, Vitale G and Pucillo C: CD40 stimulation induces
Pax5/BSAP and EBF activation through a APE/Ref-1-dependent redox
mechanism. J Biol Chem. 279:1777–1786. 2004. View Article : Google Scholar
|
|
59
|
Tell G, Zecca A, Pellizzari L, Spessotto
P, Colombatti A, Kelley MR, Damante G and Pucillo C: An
'environment to nucleus' signaling system operates in B
lymphocytes: Redox status modulates BSAP/Pax-5 activation through
Ref-1 nuclear translocation. Nucleic Acids Res. 28:1099–1105. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Polikowsky HG, Wogsland CE, Diggins KE,
Huse K and Irish JM: Cutting Edge: Redox signaling hypersensitivity
distinguishes human germinal center B cells. J Immunol.
195:1364–1367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang M, Zhou F, Luo Y, Deng X, Chen X and
Yi Q: The transcription factor PPARA mediates SIRT1 regulation of
NCOR1 to protect damaged heart cells. Cardiovasc Diagn Ther.
14:832–847. 2024. View Article : Google Scholar : PubMed/NCBI
|
